PPBT Key Statistics, Chart & Performance
The current stock price of PPBT is 0.6912 USD. In the past month the price decreased by -16.29%. In the past year, price decreased by -82.23%.
PPBT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.37 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.69 | 492.44B | ||
| MRK | MERCK & CO. INC. | 12.55 | 274.34B | ||
| PFE | PFIZER INC | 7.96 | 144.87B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.72B | ||
| ZTS | ZOETIS INC | 20.06 | 56.04B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.77 | 23.19B | ||
| VTRS | VIATRIS INC | 5.48 | 14.70B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.45 | 11.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.53B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About PPBT
Company Profile
Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Company Info
PURPLE BIOTECH LTD-ADR
4 Oppenheimer St., Science Park
Rehovot 7670104 IL
CEO: Gil Efron
Employees: 9
Phone: 97239333121
PURPLE BIOTECH LTD-ADR / PPBT FAQ
Can you describe the business of PURPLE BIOTECH LTD-ADR?
Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
What is the stock price of PURPLE BIOTECH LTD-ADR today?
The current stock price of PPBT is 0.6912 USD. The price decreased by -2.57% in the last trading session.
Does PURPLE BIOTECH LTD-ADR pay dividends?
PPBT does not pay a dividend.
What is the ChartMill technical and fundamental rating of PPBT stock?
PPBT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is PPBT stock listed?
PPBT stock is listed on the Nasdaq exchange.
When does PURPLE BIOTECH LTD-ADR (PPBT) report earnings?
PURPLE BIOTECH LTD-ADR (PPBT) will report earnings on 2026-03-03.
PPBT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PPBT. When comparing the yearly performance of all stocks, PPBT is a bad performer in the overall market: 90.56% of all stocks are doing better.
PPBT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PPBT. PPBT has a bad profitability rating. Also its financial health evaluation is rather negative.
PPBT Financial Highlights
Over the last trailing twelve months PPBT reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS increased by 85.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.32% | ||
| ROE | -9.92% | ||
| Debt/Equity | 0 |